{"id":"tremelimumab-treme","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":{"setId":"6690679c-be2f-4588-a2e4-89fff74dd6be","title":"IMJUDO (TREMELIMUMAB) INJECTION, SOLUTION [ASTRAZENECA PHARMACEUTICALS LP]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CTLA-4 is an immune checkpoint protein that suppresses T cell activation. By binding to CTLA-4, tremelimumab prevents its interaction with B7 ligands on antigen-presenting cells, thereby releasing the brake on T cell proliferation and activation. This allows the immune system to mount a stronger attack against cancer cells.","oneSentence":"Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:34:43.901Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable hepatocellular carcinoma (in combination with durvalumab)"},{"name":"Mesothelioma (in combination with durvalumab)"}]},"trialDetails":[{"nctId":"NCT03057106","phase":"PHASE2","title":"Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2017-03-28","conditions":"Lung Cancer Metastatic","enrollment":301},{"nctId":"NCT02499328","phase":"PHASE1, PHASE2","title":"Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-06","conditions":"Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck","enrollment":340},{"nctId":"NCT05239169","phase":"PHASE2","title":"Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2022-05-23","conditions":"Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma","enrollment":40},{"nctId":"NCT03022500","phase":"PHASE2","title":"Pulmonary sarcomatoid_MEDI4736+Treme","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2017-05-18","conditions":"Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC","enrollment":32},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT02527434","phase":"PHASE2","title":"Study of Tremelimumab in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-11-02","conditions":"Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":64},{"nctId":"NCT03624231","phase":"PHASE2","title":"Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC","status":"COMPLETED","sponsor":"Ulrich Keilholz","startDate":"2018-08-15","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":18},{"nctId":"NCT01975831","phase":"PHASE1","title":"A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2013-12-19","conditions":"Breast Cancer, Ovarian Cancer, Colorectal Cancer","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"tremelimumab (treme)","genericName":"tremelimumab (treme)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses. Used for Unresectable hepatocellular carcinoma (in combination with durvalumab), Mesothelioma (in combination with durvalumab).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}